Search by Drug Name or NDC

    NDC 50201-7682-02 Top Value Effervescent Cold Relief 325; 2; 7.8 mg/1; mg/1; mg/1 Details

    Top Value Effervescent Cold Relief 325; 2; 7.8 mg/1; mg/1; mg/1

    Top Value Effervescent Cold Relief is a ORAL TABLET, EFFERVESCENT in the HUMAN OTC DRUG category. It is labeled and distributed by Tower Laboratories Ltd. The primary component is ASPIRIN; CHLORPHENIRAMINE MALEATE; PHENYLEPHRINE BITARTRATE.

    Product Information

    NDC 50201-7682
    Product ID 50201-7682_c1bd1648-940b-1df0-e053-2995a90ab996
    Associated GPIs
    GCN Sequence Number n/a
    GCN Sequence Number Description n/a
    HIC3 n/a
    HIC3 Description n/a
    GCN n/a
    HICL Sequence Number n/a
    HICL Sequence Number Description n/a
    Brand/Generic n/a
    Proprietary Name Top Value Effervescent Cold Relief
    Proprietary Name Suffix n/a
    Non-Proprietary Name Aspirin, Chlorpheniramine Maleate, Phenylephrine Bitartrate
    Product Type HUMAN OTC DRUG
    Dosage Form TABLET, EFFERVESCENT
    Route ORAL
    Active Ingredient Strength 325; 2; 7.8
    Active Ingredient Units mg/1; mg/1; mg/1
    Substance Name ASPIRIN; CHLORPHENIRAMINE MALEATE; PHENYLEPHRINE BITARTRATE
    Labeler Name Tower Laboratories Ltd
    Pharmaceutical Class Adrenergic alpha1-Agonists [MoA], Anti-Inflammatory Agents, Non-Steroidal [CS], Cyclooxygenase Inhibitors [MoA], Decreased Platelet Aggregation [PE], Decreased Prostaglandin Production [PE], Histamine H1 Receptor Antagonists [MoA], Histamine-1 Receptor An
    DEA Schedule n/a
    Marketing Category OTC MONOGRAPH FINAL
    Application Number part341
    Listing Certified Through 2024-12-31

    Package

    NDC 50201-7682-02 (50201768202)

    NDC Package Code 50201-7682-2
    Billing NDC 50201768202
    Package 10 POUCH in 1 CARTON (50201-7682-2) / 2 TABLET, EFFERVESCENT in 1 POUCH
    Marketing Start Date 2010-07-01
    NDC Exclude Flag N
    Pricing Information N/A

    Standard Product Labeling (SPL)/Prescribing Information SPL 440a00b1-7960-0cc4-e054-00144ff8d46c Details

    Revised: 5/2021